Abstract:The direct killing of cancer cells by cytotoxic T-lymphocytes (CTL) is critical for achieving effective antitumor immune responses. While several tumor-intrinsic mutations have been identified that promote evasion to CTL killing, there remains a paucity of data cataloging how individual genetic perturbations impact cancer cell fitness under immunotherapeutic selection pressure. Towards this, genetic screens using the CRISPR-Cas9 system have recently been employed, identifying novel intrinsic genetic regulators of cancer immunotherapy fitness. While these initial studies demonstrate the significant potential of unbiased genetic screens for discovery of novel immunotherapy targets, they have been limited in application to a small number of disease models. As such, the degree to which intrinsic genetic perturbations robustly modulate immunotherapy fitness across diverse cancer genotypes remains largely unexplored. To circumvent this knowledge gap, we performed genetic screens across a panel of commonly utilized syngeneic murine cancer cell lines to identify a core set of genes that render cancer cells more sensitive or resistant to CTL killing across diverse genetic backgrounds. An optimized genome-scale gRNA library targeting ~19,000 protein-coding genes in the murine genome (termed mTKO; mouse Toronto Knockout) was created in an analogous manner to our human library. Screens were performed in multiple murine cell lines engineered to express model tumor-associated antigens. Cells were propagated in the presence or absence of preactivated antigen-specific CTLs, and gRNA abundance was quantified by illumina sequencing to identify perturbed genes enriched or depleted in CTL treated versus untreated populations. These screens uncovered known genetic regulators of CTL killing including immune checkpoints (Cd274), antigen presentation machinery (B2m, Tap1/2) and interferon signaling components (Socs1, Jak1/2, Ifngr1/2), benchmarking the utility of this approach. Importantly, we leveraged this dataset to derive a core list of genes whose perturbation significantly modulates cancer-cell fitness to CTL killing across the majority of genotypes screened. Gene set enrichment analysis revealed critical roles for cytokine and TLR signaling, the NF-κB and MAPK pathways as well as the antiviral and antigen presentation machineries. As such, our dataset represents the first step towards a comprehensive understanding of the functional genomic landscape of CTL-mediated cytotoxicity. Citation Format: Keith Lawson, Xiaoyu Zhang, Cris Sousa, Rummy Akthar, Zi Fan, Eiru Kim, Medina Colic, Amy Tong, Katie Chan, Qian Huang, Xiaowei Wang, Kevin Brown, Michael Aregger, Antonio Finelli, Laurie Ailles, Traver Hart, Gillian Kingsbury, Charles Kung, Jason Moffat. Functional genomic landscape of T-cell mediated cytotoxicity [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B60.

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets

Common pitfalls in preclinical cancer target validation

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Functional genomic landscape of T-cell mediated cytotoxicity.

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Abstract 5371: Multimodal CRISPR activation screens reveal new mechanisms to sensitize cancer cells to targeted T cell mediated elimination

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning

Using Antagonistic Pleiotropy to Design a Chemotherapy-Induced Evolutionary Trap to Target Drug Resistance in Cancer

Non-oncogene dependencies: Novel opportunities for cancer therapy

Targeting CDK4 Overcomes EMT-mediated Tumor Heterogeneity and Therapeutic Resistance in KRAS-mutant Lung Cancer

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality

Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance

Targeting Tumor Suppressor Genes for Cancer Therapy

Genetic vulnerabilities upon inhibition of DNA damage response

Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Non-kinase targets of protein kinase inhibitors

Abstract PR014: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers

Abstract LB357: CRISPR-Cas9 targeting of somatic mutations selectively kills cancer cells